Valneva SE/€VLA
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Valneva SE
Valneva SE is a biotechnology company specializing in the development and commercialization of vaccines for infectious diseases. The company's portfolio includes vaccines for diseases such as Japanese encephalitis and cholera. Valneva is actively engaged in developing vaccines for Lyme disease and chikungunya. Founded in 2013 through the merger of Intercell AG and Vivalis, Valneva is headquartered in Saint-Herblain, France. The company operates primarily in Europe but has a global reach through various strategic partnerships and licensing agreements. Valneva's competitive strength lies in its focus on addressing unmet medical needs with its diverse pipeline of innovative vaccine candidates.
Ticker
€VLA
Sector
Primary listing
PAR
Employees
700
Headquarters
Website
Valneva SE Metrics
BasicAdvanced
€635M
-
-€0.42
1.01
-
Price and volume
Market cap
€635M
Beta
1.01
52-week high
€5.36
52-week low
€1.73
Average daily volume
374K
Financial strength
Current ratio
2.266
Quick ratio
1.476
Long term debt to equity
79.522
Total debt to equity
105.628
Interest coverage (TTM)
-2.10%
Profitability
EBITDA (TTM)
-33.421
Gross margin (TTM)
9.86%
Net profit margin (TTM)
-34.15%
Operating margin (TTM)
-25.18%
Effective tax rate (TTM)
-3.35%
Revenue per employee (TTM)
€280,000
Management effectiveness
Return on assets (TTM)
-6.58%
Return on equity (TTM)
-38.01%
Valuation
Price to revenue (TTM)
2.997
Price to book
3.3
Price to tangible book (TTM)
3.78
Price to free cash flow (TTM)
-21.881
Free cash flow yield (TTM)
-4.57%
Free cash flow per share (TTM)
-0.17
Growth
Revenue change (TTM)
25.47%
Earnings per share change (TTM)
78.90%
3-year revenue growth (CAGR)
-13.60%
10-year revenue growth (CAGR)
11.66%
3-year earnings per share growth (CAGR)
-34.59%
10-year earnings per share growth (CAGR)
7.65%
Bulls say / Bears say
The EMA lifted its temporary restriction on Ixchiq for adults 65 and older, reopening access to the vaccine in the EU after a safety review.
Ixchiq generated €7.5 million, representing over 8% of Valneva's total product sales in the first half of 2025, showing the vaccine's early commercial momentum.
Valneva upheld its full-year financial guidance despite the FDA suspension, reflecting its confidence in a diversified commercial and R&D pipeline.
The FDA suspended the U.S. license for Ixchiq effective immediately, stopping all distribution and sales in the U.S., which is a key revenue channel.
The suspension followed reports of four serious adverse events with symptoms similar to chikungunya, intensifying urgent safety concerns surrounding Ixchiq.
Valneva is considering a potential permanent withdrawal of Ixchiq from the U.S. market, which creates major uncertainty for its U.S. growth prospects.
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Valneva SE stock?
Valneva SE (VLA) has a market cap of €635M as of September 08, 2025.
What is the P/E ratio for Valneva SE stock?
The price to earnings (P/E) ratio for Valneva SE (VLA) stock is 0 as of September 08, 2025.
Does Valneva SE stock pay dividends?
No, Valneva SE (VLA) stock does not pay dividends to its shareholders as of September 08, 2025.
When is the next Valneva SE dividend payment date?
Valneva SE (VLA) stock does not pay dividends to its shareholders.
What is the beta indicator for Valneva SE?
Valneva SE (VLA) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.